Phoenix, AZ-March 4, 2009-Mission3, Inc., a leading provider of program delivery for the Life Sciences industry, announced today that it has entered into a strategic partnership with Re@lityCorp in order to provide cutting edge technology to emerging Life Science companies. With Re@lityCorp’s unparalleled QA and Testing expertise, along with their trusted practices and standards, and Mission3’s robust suite of
project planning, document management, regulatory submission, and collaborative authoring, the alliance promises to provide efficient, accurate execution of services for client companies in today’s challenging operational environment.
“We are pleased to partner with a company like Re@lityCorp. Given their expertise in the validation and testing arena and their knowledge of technology delivery via SaaS, this partnership can really highlight the value chain for life science companies. With the incredible tightness in the economy and capital markets right now, both Mission3 and Re@lityCorp offer companies mission critical technology without making huge
investments in working capital as well as time and resources.”, said Dirk Karsten Beth, President and Founder of Mission3.
“Our clients are always under significant time and resource constraints to deliver projects on schedule and within budget. They are looking for timely and easily accessible ways to access, maintain, approve, retrieve, and collaborate on project related documentation. Mission3’s web based, project integrated electronic documentation management solution is a home run for our clients and users. We are really looking forward to extend the Mission3 platform and value to our client base”, said Carlton Schowe, President of Re@lityCorp.
About Mission3, Inc.
Mission3 is a leading provider of on-demand program delivery software that merges cutting edge technology with affordability, exclusively for the unique needs of the Life Sciences industry. Mission3 OnDemand is a fully integrated, 21 CFR Part 11 compliant, Document, Project, and Regulatory Submission Management suite that is truly web-based and offered in an collaborative, on-demand (SaaS) environment. Designed for rapid deployment and ease of use, Mission3 OnDemand 3.0 manages all documents within business areas governed by world wide regulatory bodies and corresponding submissions. For more information go to: www.mission3.com
About Re@lity Corp
Re@lityCorp provides state-of-art and industry leading outsourced QA data validation solutions. Our Software as a Service (SaaS) offers our clients unparallel new configuration and amendment deployment speed and leading edge functionality that typically saves our clients up to a 50% reduction in project time and cost without compromising quality. Re@lityCorp’s QA testing platform offers a very compelling value
proposition to our customers. For more information go to: www.realitycorp.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.